Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Pharma Domain KSA SWOT & PESTLE Analysis

ID : 52638653| Apr 2020| 15 pages

COMPANY PROFILE -Pharma Domain KSA (Kingdom of Saudi Arabia)

Business Sector :Pharmaceutical

Operating Geography :Kingdom of Saudi Arabia

About Pharma Domain KSA (Kingdom of Saudi Arabia) :

Saudi Arabia is one of the largest pharmaceutical markets in the Middle East, and its expansion over recent years can be attributed to a growing population, an increase in non-communicable diseases and strong state support for health services, with major government investment in new hospitals and clinics. The latest industry data reveals the Kingdom’s pharmaceutical market is expected to be valued at $10.74 billion (SR40.1 billion) by 2023

Pharma Domain KSA (Kingdom of Saudi Arabia) Revenue :

Competitive Analysis of Pharma Domain KSA (Kingdom of Saudi Arabia)

SWOT
PESTLE
The SWOT analysis for Pharma Domain – KSA (Kingdom of Saudi Arabia) is presented below:
Strengths
Weaknesses
1. Strong economic vision and strategic geographic location
2. Increasing multinational pharma investments
3. KSA - one of the largest pharmaceutical markets in the Middle East
1. Majority of pharmaceuticals manufactured overseas
Opportunities
Threats
1. National Transformation Program (NTP) to boost domestic pharma manufacturing
2. Government focus on spending on health and social development
3. Increasing preference for branded medications in KSA
4. Collaboration between domestic and international players
1. Weakening economic conditions
2. Accusations of committing glaring human rights abuses
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of Pharma Domain KSA (Kingdom of Saudi Arabia)

 

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

1. Weakening economic conditions: Low oil prices have caused a slowdown of the KSA economy which has affected consumer and business sentiment and has led to a lower GDP growth. The reduced oil production of 2019 in the kingdom is a result of an OPEC+ agreement that the country has signed. GDP growth has thus gone down to 1.7% year-on-year (y/y) in Q1 2019 as compared to 2.4% in 2018. This is further expected to fall to 0% in 2019 owing to poor global outlooks. The September attacks on several Saudi oil facilities also caused supply disruption and affected overall 2019 growth. Investments in the non-oil sectors like pharmaceuticals are also expected to get affected.

2. Accusations of committing glaring human rights abuses: Investors have become wary of entering the KSA market owing to several recent allegations regarding human rights abuses committed within the kingdom. Khashoggi's death, an anti-corruption purge that has supposedly led to the arbitrary arrests of hundreds of businessmen and royals and the detention and alleged torture of women's rights activists have all served to stain the kingdom’s image and make it a risky market for investment. A firm denial of all these allegations however has not been able to remove investor doubts. The international pharmaceutical involvement in the KSA market is likely to be affected by these events.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Pharma Domain KSA (Kingdom of Saudi Arabia) Analysis Report

1. Saudi Arabia’s pharma market to reach $10.74 billion by 2022: http://saudigazette.com.sa/article/575657

2. Saudi Arabia’s Bold Ambition to Become a Regional Pharma Hub: https://pharmaboardroom.com/articles/saudi-arabias-bold-ambition-to-become-a-pharma-hub/

3. Aurobindo Pharma to build pharmaceutical factory in Saudi Arabia: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-to-build-pharmaceutical-factory-in-saudi-arabia/articleshow/50528783.cms?from=mdr

4. Sanofi Reinforces Its Local Presence In Saudi Arabia With The Inauguration Of Its Plant In KAEC: https://www.kaec.net/press_releases/sanofi-reinforces-its-local-presence-in-saudi-arabia-with-the-inauguration-of-its-plant-in-kaec/

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Pharma Domain KSA SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). Pharma Domain KSA SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/pharma-domain-ksa/ [Accessed 03 Jul, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Pharma Domain – KSA SWOT and PESTLE analysis has been conducted and reviewed by senior analysts from Barakaat Consulting.

Copyright of Pharma Domain – KSA SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
Pharma Domain KSA SWOT & PESTLE Analysis
Price : USD 12.53